A Technical Comparison of Human Papillomavirus Genotyping Assays from a Population-Based Cervical Cancer Screening in South Central Ethiopia.
HPV PCR test accuracy
HPV test complexity
HPV testing
LMIC
analytical performance
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
02
2022
accepted:
27
05
2022
entrez:
8
8
2022
pubmed:
9
8
2022
medline:
9
8
2022
Statut:
epublish
Résumé
High-risk Human Papillomavirus (HPV) is the most important cause of cervical cancer. The highest burden of disease is seen in Low- and Low-Middle-Income Countries (LMIC). Several new HPV screening assays have been developed for high-risk HPV (hr-HPV) testing. We compared the performance and adequacy of three HPV genotyping assays on samples from a population of rural women in south-central Ethiopia. One hundred and ten cervical swabs from rural women screened for HPV were assayed. HPV DNA was tested using MPG-Luminex Assay, Anyplex II HPV HR Detection, and EUROArray HPV. MPG-Luminex Assay was used as a reference method to compute the sensitivity and specificity of the two commercial assays in detecting hr-HPV infections. Of the 110 samples, MPG-Luminex Assay found 18.2% positive for the 14 hr-HPV and 7.3% for the probable hr-HPV genotypes. Anyplex™ II HPV HR Detection assay and EUROArray HPV Assay identified 21.82% and 12.7% samples, respectively, for the 14 hr-HPVs and both 7.3% for the probable hr-HPV genotypes (κ=0.734). Among the 14 hr-HPV genotypes, the genotype-specific agreement of the three HPV genotyping assays was moderate or better for HPV16, 31, 35, 39, 52, 56, 66 and 68. The aggregated sensitivity in detecting the 14 hr-HPV infections of Anyplex™ II HPV HR Detection and EUROArray HPV assays was high, 100% and 70%, respectively. The specificities of Anyplex™ II HPV HR Detection and EUROArray HPV were 95.6% and 100%, respectively. The three evaluated assays showed similar analytical performance in the detection of hr-HPV infections and moderate or better concordance in HPV genotyping. This study is part of the ongoing cluster-randomized trial that has been registered in clinicaltrials.gov (NCT03281135) on September 13, 2017.
Identifiants
pubmed: 35937937
doi: 10.2147/CMAR.S360712
pii: 360712
pmc: PMC9346300
doi:
Banques de données
ClinicalTrials.gov
['NCT03281135']
Types de publication
Journal Article
Langues
eng
Pagination
2253-2263Informations de copyright
© 2022 Teka et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest in relation to this work.
Références
J Clin Microbiol. 2008 Mar;46(3):1050-9
pubmed: 18199790
Int J Cancer. 2017 May 15;140(10):2192-2200
pubmed: 28006858
Cancer Prev Res (Phila). 2019 Sep;12(9):609-616
pubmed: 31337647
J Clin Virol. 2016 Mar;76 Suppl 1:S3-S13
pubmed: 26601820
Front Public Health. 2017 Nov 20;5:307
pubmed: 29209603
Clin Microbiol Infect. 2015 Sep;21(9):817-26
pubmed: 25936581
Clin Microbiol Infect. 2020 Sep;26(9):1144-1150
pubmed: 32247892
Ann Intern Med. 1997 Jan 1;126(1):91-4
pubmed: 8992938
Clin Microbiol Rev. 2003 Jan;16(1):1-17
pubmed: 12525422
Int J Cancer. 2012 Nov 1;131(9):1969-82
pubmed: 22623137
IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636
pubmed: 18354839
J Clin Virol. 2016 Mar;76:36-9
pubmed: 26809131
J Clin Microbiol. 2014 Nov;52(11):3996-4002
pubmed: 25210073
Virol J. 2012 Nov 06;9:262
pubmed: 23131123
J Clin Virol. 2009 Jun;45(2):100-4
pubmed: 19394266
Papillomavirus Res. 2019 Jun;7:173-175
pubmed: 31002883
PLoS One. 2020 Sep 1;15(9):e0238291
pubmed: 32870941
Eur J Clin Microbiol Infect Dis. 2016 Jun;35(6):1033-6
pubmed: 27048314
Cancer Prev Res (Phila). 2020 Jul;13(7):593-600
pubmed: 32371553
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21
pubmed: 26522865
Clin Microbiol Infect. 2020 May;26(5):579-583
pubmed: 31539637
BMJ. 2016 Oct 4;355:i4924
pubmed: 27702796
J Med Virol. 2011 Jun;83(6):1042-7
pubmed: 21503918
Int J Cancer. 2021 Feb 1;148(3):723-730
pubmed: 32875552
Clin Microbiol Infect. 2021 Aug;27(8):1083-1095
pubmed: 33975008
Nat Rev Cancer. 2018 Apr;18(4):240-254
pubmed: 29497146
J Pathol. 1999 Sep;189(1):12-9
pubmed: 10451482
Am J Clin Pathol. 2010 Aug;134(2):193-9
pubmed: 20660320
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Papillomavirus Res. 2017 Dec;4:79-84
pubmed: 29179874
Am J Obstet Gynecol. 2017 Mar;216(3):264.e1-264.e7
pubmed: 27825977